If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
===== Anguimorpha ===== Clade Paleoanguimorpha Family Shinisauridae Shinisaurus crocodilurus, Chinese crocodile lizard, (2017) Clade Neoanguimorpha Family Helodermatidae Heloderma charlesbogerti, Guatemalan beaded lizard, (2022) Family Anguidae Dopasia gracilis, Burmese glass lizard, (2015)
== Determination == Death was historically believed to be an event that coincided with the onset of clinical death. It is now understood that death is a series of physical events, not a single one, and determination of permanent death is dependent on other factors beyond simple cessation of breathing and heartbeat. Clinical death that occurs unexpectedly is treated as a medical emergency. CPR is initiated. In a United States hospital, a Code Blue is declared and Advanced Cardiac Life Support procedures used to attempt to restart a normal heartbeat. This effort continues until either the heart is restarted, or a physician determines that continued efforts are useless and recovery is impossible. If this determination is made, the physician pronounces legal death and resuscitation efforts stop. If clinical death is expected due to terminal illness or withdrawal of supportive care, often a Do Not Resuscitate (DNR) or "no code" order is in place. This means that no resuscitation efforts are made, and a physician or nurse may pronounce legal death at the onset of clinical death. A patient with working heart and lungs who is determined to be brain dead can be pronounced legally dead without clinical death occurring. However, some courts have been reluctant to impose such a determination over the religious objections of family members, such as in the Jesse Koochin case. Similar issues were also raised by the case of Mordechai Dov Brody, but the child died before a court could resolve the matter.
== Side effects == The most common adverse effect is headache, which occurs in 1–2% of patients. Rashes occur in fewer than 1% of patients. Other described skin reactions include itching, urticaria, angioedema, erythema multiforme, and erythema nodosum.
== Interactions based on pharmacokinetics == Pharmacokinetics is the field of research studying the chemical and biochemical factors that directly affect dosage and the half-life of drugs in an organism, including absorption, transport, distribution, metabolism and excretion. Compounds may affect any of those process, ultimately interfering with the flux of drugs in the human body, increasing or reducing drug availability.
Classically, the iron in oxyhemoglobin is seen as existing in the iron(II) oxidation state. However, the complex of oxygen with heme iron is diamagnetic, whereas both oxygen and high-spin iron(II) are paramagnetic. Experimental evidence strongly suggests heme iron is in the iron(III) oxidation state in oxyhemoglobin, with the oxygen existing as superoxide anion (O2•−) or in a covalent charge-transfer complex.
Sources: en.wikipedia.org
== Music and lyrics == With songs written primarily on the road, the material is darker than Facelift. "We did a lot of soul searching on this album. There's a lot of intense feelings." Cantrell said, "We deal with our daily demons through music. All of the poison that builds up during the day we cleanse when we play". Drug use was front and center as a lyrical theme on the album. Three tracks ("Junkhead", "God Smack", and "Hate to Feel") specifically reference heroin use and its effects. Staley revealed that the album is semi-conceptual and that there are two basic themes in it. The first theme is about "dealing with kind of a personal anguish and turmoil, which turns into drugs to ease that pain, and being confident that that was the answer in a way. Then later on the songs start to slip down closer and closer to hell, and then he figures out that drugs were not, and are not, the way to ease that pain. Basically, it's the whole story of the last three years of my life." Staley described the other theme as being about "painful relationships and involvements with persons." Staley later expressed regret about the lyrical content of some songs on Dirt, explaining, "I wrote about drugs, and I didn't think I was being unsafe or careless by writing about them ... I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high. That's exactly what I didn't want to happen." Cantrell said in 2013: "That darkness was always part of the band, but it wasn't all about that.
Receptors of a particular type are linked to specific cellular biochemical pathways that correspond to the signal. While numerous receptors are found in most cells, each receptor will only bind with ligands of a particular structure. This has been analogously compared to how locks will only accept specifically shaped keys. When a ligand binds to a corresponding receptor, it activates or inhibits the receptor's associated biochemical pathway, which may also be highly specialised. Receptor proteins can be also classified by the property of the ligands. Such classifications include chemoreceptors, mechanoreceptors, gravitropic receptors, photoreceptors, magnetoreceptors and gasoreceptors.
Albumin is a family of globular proteins, the most common of which are the serum albumins. All of the proteins of the albumin family are water-soluble, moderately soluble in concentrated salt solutions, and experience heat denaturation. Albumins are commonly found in blood plasma and differ from other blood proteins in that they are not glycosylated. Substances containing albumins are called albuminoids. A number of blood transport proteins are evolutionarily related in the albumin family, including serum albumin, alpha-fetoprotein, vitamin D-binding protein and afamin. This family is only found in vertebrates. Albumins in a less strict sense can mean other proteins that coagulate under certain conditions. See Other albumin types for lactalbumin, ovalbumin and plant "2S albumin". Albumins in general are transport proteins that bind to various ligands and carry them around. Human types include:
Factors that affect absorption include: The way a drug product is designed and manufactured Its physical and chemical properties Other ingredients it contains The physiologic characteristics of the person taking the drug How the drug is stored Types of absorption in pharmacokinetics include the following: Instantaneous absorption: absorption is nearly immediate. A common example is bolus intravenous injection. Zero-order absorption: rate of absorption is constant. A common example is continuous intravenous infusion. First-order absorption: rate of absorption is proportional to the amount of drug remaining to be absorbed. Representative examples include typical cases of oral administration, subcutaneous injection, and intramuscular injection. Gastrointestinal transit time Flip–flop kinetics Absorption of Drugs
20983Bi + 5424Cr → 262107Bh + n This discovery was further substantiated by their detailed measurements of the alpha decay chain of the produced bohrium atoms to previously known isotopes of fermium and californium. The IUPAC/IUPAP Transfermium Working Group (TWG) recognised the GSI collaboration as official discoverers in their 1992 report.
Sources: en.wikipedia.org
In December 2007, Takeda submitted a New Drug Application (NDA) for alogliptin to the United States Food and Drug Administration (FDA), after positive results from Phase III clinical trials. In September 2008, the company also filed for approval in Japan, winning approval in April 2010. The company also filed a marketing authorisation application elsewhere outside the United States, which was withdrawn in June 2009 needing more data. The first NDA failed to gain approval and was followed by a pair of NDAs (one for alogliptin and a second for a combination of alogliptin and pioglitazone) in July 2011. In 2012, Takeda received a negative response from the FDA on both of these NDAs, citing a need for additional data.
Ghana lies on the Gulf of Guinea in West Africa, a few degrees north of the Equator. It covers 238,540 km2 (92,101 sq mi) and has an Atlantic coastline of about 560 kilometres (350 miles). It is situated between latitudes 4°45′N and 11°N, and longitudes 1°15′E and 3°15′W. The Prime Meridian passes through Tema, near Accra, making Ghana the country closest to the intersection of the Prime Meridian and the Equator (0°, 0°), located offshore in the Atlantic. Grasslands mixed with south coastal shrublands and forests dominate Ghana, with forest extending northward from the coast 320 kilometres (200 miles) and eastward for a maximum of about 270 kilometres (170 miles) with locations for mining of industrial minerals and timber. Ghana is home to five terrestrial ecoregions: Eastern Guinean forests, Guinean forest–savanna mosaic, West Sudanian savanna, Central African mangroves, and Guinean mangroves. The White Volta River and its tributary Black Volta, flow south through Ghana to Lake Volta, the world's third-largest reservoir by volume and largest by surface area, formed by the hydroelectric Akosombo Dam, completed in 1965. The Volta flows out of Lake Volta into the Gulf of Guinea. The northernmost part of Ghana is Pulmakong and the southernmost part of Ghana is Cape Three Points. Ghana consists of low coastal plains, forested hills in the centre, and savanna in the north.
Neutrophil Neutrophils are the most common white blood cells in normal adult blood. When stained with a Romanowsky stain, they exhibit a multi-lobed nucleus and pink cytoplasm that contains small purple granules. The neutrophil count is normally higher in newborns and pregnant women than in other groups. Outside of these conditions, increased neutrophil counts (neutrophilia) are associated with bacterial infection, inflammation, and various forms of physiological stress. Neutrophil counts can become extremely high in response to some infections and inflammatory states, which is termed leukemoid reaction because the high white blood cell count mimics leukaemia. Neutrophilia may also occur in myeloproliferative disorders.Neutropenia, meaning a low neutrophil count, may occur as a response to drug treatment (especially chemotherapy) or in certain infections, such as tuberculosis and Gram-negative sepsis. Neutropenia also occurs in many hematologic disorders, such as leukaemia and myelodysplastic syndrome, and in a variety of autoimmune and congenital diseases. A neutrophil count below the reference interval may be normal in individuals of certain ethnicities; this is termed benign ethnic neutropenia. Very low neutrophil counts are associated with immunosuppression. When stimulated by infection or inflammation, neutrophils may develop abnormal features in their cytoplasm, such as toxic granulation, toxic vacuolation and Döhle bodies. These features, which are caused by the release of cytokines, are collectively known as toxic changes.
EC 1, Oxidoreductases: catalyze oxidation/reduction reactions EC 2, Transferases: transfer a functional group (e.g. a methyl or phosphate group) EC 3, Hydrolases: catalyze the hydrolysis of various bonds EC 4, Lyases: cleave various bonds by means other than hydrolysis and oxidation EC 5, Isomerases: catalyze isomerization changes within a single molecule EC 6, Ligases: join two molecules with covalent bonds. EC 7, Translocases: catalyze the movement of ions or molecules across membranes, or their separation within membranes. These sections are subdivided by other features such as the substrate, products, and chemical mechanism. An enzyme is fully specified by four numerical designations. For example, hexokinase (EC 2.7.1.1) is a transferase (EC 2) that adds a phosphate group (EC 2.7) to a hexose sugar, a molecule containing an alcohol group (EC 2.7.1).
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.